Cited 28 times in
Intermediate-term outcomes of robot-assisted laparoscopic nephroureterectomy in upper urinary tract urothelial carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김광현 | - |
dc.contributor.author | 나군호 | - |
dc.contributor.author | 신태영 | - |
dc.contributor.author | 임세이캣 | - |
dc.contributor.author | 정병하 | - |
dc.contributor.author | 최영득 | - |
dc.contributor.author | 홍성준 | - |
dc.date.accessioned | 2014-12-18T09:37:50Z | - |
dc.date.available | 2014-12-18T09:37:50Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1558-7673 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/88531 | - |
dc.description.abstract | BACKGROUND: The purpose of this study was to evaluate the intermediate-term oncological outcomes after (RAL-NU) for UUT-UC. PATIENTS AND METHODS: Between May 2007 and December 2010, 32 patients with UUT-UC underwent RAL-NU. Data were obtained from a prospectively maintained database. RESULTS: Median patient age was 66.5 years. Final pathological stage was pathologic stage Ta (pTa) in 12.5% (n = 4) of patients, pT1 in 28.1% (n = 9), pT2 in 18.8% (n = 6), pT3 in 40.6% (n = 13), and pT4 in 0%. High-grade lesions were present in 81.2% (n = 26) of patients and multifocal disease was present in 25.0% (n = 8). Positive surgical margins occurred in 1 patient. Median follow-up was 45.5 months (range, 24-65). At 2 and 5 years, overall survival was 81.3% and 60.9%; cancer-specific survival was 87.3% and 75.8%, and nonurothelial recurrence-free survival was 71.5% and 68.1%, respectively. On univariate analysis, female sex, positive surgical margins, and pathological tumor stage pT2 and higher are associated with reduced recurrence-free survival (P = .035 and .011, respectively). On multivariate analysis, only female sex and pathological stage pT2 or higher were significant factors (P = .020 and .049, respectively). No factors were found to affect cancer-specific survival. CONCLUSION: To our knowledge, this represents the largest and longest follow-up after RAL-NU to date. Intermediate-term oncological outcomes seem comparable with those of open and laparoscopic nephroureterectomy. We recommend further larger studies with longer follow-up periods to further define the role of RAL-NU in the treatment of UUT-UC. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | CLINICAL GENITOURINARY CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kidney/surgery | - |
dc.subject.MESH | Kidney Neoplasms/mortality | - |
dc.subject.MESH | Kidney Neoplasms/pathology | - |
dc.subject.MESH | Kidney Neoplasms/surgery | - |
dc.subject.MESH | Laparoscopy | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Nephrectomy/methods* | - |
dc.subject.MESH | Robotics/methods* | - |
dc.subject.MESH | Sex Factors | - |
dc.subject.MESH | Survival | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Urinary Tract/pathology | - |
dc.subject.MESH | Urinary Tract/surgery* | - |
dc.subject.MESH | Urologic Neoplasms/pathology | - |
dc.subject.MESH | Urologic Neoplasms/surgery* | - |
dc.subject.MESH | Urothelium/pathology | - |
dc.subject.MESH | Urothelium/surgery* | - |
dc.title | Intermediate-term outcomes of robot-assisted laparoscopic nephroureterectomy in upper urinary tract urothelial carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨기과학) | - |
dc.contributor.googleauthor | Sey Kiat Lim | - |
dc.contributor.googleauthor | Tae-Young Shin | - |
dc.contributor.googleauthor | Kwang Hyun Kim | - |
dc.contributor.googleauthor | Byung Ha Chung | - |
dc.contributor.googleauthor | Sung Joon Hong | - |
dc.contributor.googleauthor | Young Deuk Choi | - |
dc.contributor.googleauthor | Koon Ho Rha | - |
dc.identifier.doi | 10.1016/j.clgc.2013.04.027 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00319 | - |
dc.contributor.localId | A01227 | - |
dc.contributor.localId | A02168 | - |
dc.contributor.localId | A03371 | - |
dc.contributor.localId | A03607 | - |
dc.contributor.localId | A04111 | - |
dc.contributor.localId | A04402 | - |
dc.relation.journalcode | J00575 | - |
dc.identifier.eissn | 1938-0682 | - |
dc.identifier.pmid | 23810441 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S1558767313000888 | - |
dc.subject.keyword | Oncological outcomes | - |
dc.subject.keyword | Overall survival | - |
dc.subject.keyword | Recurrence | - |
dc.subject.keyword | TCC ureter | - |
dc.subject.keyword | Transitional cell | - |
dc.contributor.alternativeName | Kim, Kwang Hyun | - |
dc.contributor.alternativeName | Rha, Koon Ho | - |
dc.contributor.alternativeName | Shin, Tae Young | - |
dc.contributor.alternativeName | Lim, Sey Kiat | - |
dc.contributor.alternativeName | Chung, Byung Ha | - |
dc.contributor.alternativeName | Choi, Young Deuk | - |
dc.contributor.alternativeName | Hong, Sung Joon | - |
dc.contributor.affiliatedAuthor | Kim, Kwang Hyun | - |
dc.contributor.affiliatedAuthor | Rha, Koon Ho | - |
dc.contributor.affiliatedAuthor | Shin, Tae Young | - |
dc.contributor.affiliatedAuthor | Lim, Sey Kiat | - |
dc.contributor.affiliatedAuthor | Chung, Byung Ha | - |
dc.contributor.affiliatedAuthor | Choi, Young Deuk | - |
dc.contributor.affiliatedAuthor | Hong, Sung Joon | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 11 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 515 | - |
dc.citation.endPage | 521 | - |
dc.identifier.bibliographicCitation | CLINICAL GENITOURINARY CANCER, Vol.11(4) : 515-521, 2013 | - |
dc.identifier.rimsid | 34365 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.